HRS-5965 vs Iptacopan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Paroxysmal Nocturnal Hemoglobinuria

Shared mechanism: Complement Factor B · full Paroxysmal Nocturnal Hemoglobinuria pipeline

HRS-5965

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Paroxysmal Nocturnal Hemoglobinuriaundisclosed
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT06238544 (registry estimate)

No aligned efficacy figure on record for this race.

Iptacopan · Fabhalta

Marketed by Novartis

Approved in Paroxysmal Nocturnal Hemoglobinuriasmall molecule
Partial signal

NCT04558918 · Phase 3 · completed

This randomized trial compared iptacopan with continued standard anti-C5 antibody therapy and met both main measures by a wide margin, and those measures are based on hemoglobin, a laboratory value. Patients and doctors knew which treatment was given and the trial was modest in size (97 patients), so the design falls short of the highest grade.

Next expected readout: October 2027 · NCT04747613 (registry estimate)

Reported efficacy

Marginal Proportion (Expressed as Percentages) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell Transfusions; Marginal Proportion (Expressed as Percentages) of Participants With Sustained Hemoglobin Levels of ≥ 12 g/dL in the Absence of Red Blood Cell Transfusions: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries. (met)

Result source: NCT04558918

Results for Paroxysmal Nocturnal Hemoglobinuria

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

HRS-5965: no structured comparison results are available for Paroxysmal Nocturnal Hemoglobinuria.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Iptacopan
At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries. NCT04558918 · Phase 3 · design grade: moderate · publication or press release
Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator. NCT04820530 · Phase 3 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-5965's landscape · Iptacopan's landscape